Major pharmaceutical firms are seeking to strike a balance between international opprobrium over Russia’s invasion of Ukraine and the needs of sick patients.
For Riley Griffin's latest contributions to The Japan Times, see below:
While research continues, Pfizer will evaluate the new hybrid shot against one specific to omicron and determine which should move forward by March, the firm's CEO has said.
Pfizer has been first across the finish line in nearly every leg of the COVID-19 vaccine race, but Moderna executives say their company’s mRNA technology gives it an advantage.
The industries that shepherd goods around the world on ships, planes and trucks acknowledge they aren’t ready to handle the epic challenges of shipping an eventual COVID-19 vaccine from drugmakers to billions of people. Already stretched thin by the pandemic, freight companies face problems ranging ...